David Bernstein
Pediatric Infectious Diseases · Cincinnati, OHNPI 1336163021
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $55,710 of the $67,450 with a category attached, or 82.6%. 21 manufacturers reported payments, led by Modernatx, Inc. at 34.9% of the total. Reporting peaked in 2019 at $22,154 and has fallen 66.6% since, to $7,401 in 2025. Among pediatric infectious diseases clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 147 payments — averaging $458.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Modernatx, Inc.$24K
- Merck$11K
- Pfizer$8K
- Alk-abello, Inc$8K
- Dynavax Technologies Corporation$7K
- Roche Diagnostics Corporation$5K
- plus $5K from 15 others
Across 454 payments — averaging $3838.12 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$772K
- GSK$410K
- Gilead$211K
- Sanofi US Services Inc.$107K
- Chiesi USA, Inc.$82K
- Novartis$58K
- plus $103K from 5 others
What the payments were for
- Consulting fees$55,71083%
- Speaking & faculty fees$6,0009%
- Travel & lodging$3,3555%
- Food & beverage$2,3864%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Modernatx, Inc. | 38 | $23,510 |
| Merck | 10 | $10,529 |
| Pfizer | 2 | $8,230 |
| Alk-abello, Inc | 9 | $8,119 |
| Dynavax Technologies Corporation | 7 | $6,863 |
| Roche Diagnostics Corporation | 3 | $5,158 |
| GSK | 25 | $1,631 |
| Sanofi Pasteur Inc. | 12 | $1,451 |
| Mirum Pharmaceuticals, Inc. | 1 | $770 |
| Novartis | 4 | $230 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $198 |
| Sanofi | 4 | $171 |
| Teva Pharmaceuticals USA, Inc. | 6 | $156 |
| Regeneron Healthcare Solutions, Inc. | 3 | $136 |
| AstraZeneca | 8 | $125 |
| Covis Pharma GmbH | 2 | $44 |
| Kaleo, Inc. | 2 | $36 |
| Grifols USA, LLC | 2 | $35 |
| Cycle Pharmaceuticals Inc | 1 | $25 |
| AbbVie | 1 | $21 |
| Genentech USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRUMENBA$8,100
- Odactra$8,018
- V160$6,027
- POC cobas Liat Analyzer, Assays, Controls and Accessories$5,158
- Heplisav-B$4,950
- NO PRODUCT DISCUSSED$1,217
- Livmarli$770
- DUPIXENT$101
How this compares
$67,450 in reported general payments places this provider in the 95th percentile of 43 pediatric infectious diseases providers in Ohio.
Other pediatric infectious diseases in Cincinnati
- Robert FrenckCincinnati$77K
- Lara Danziger-IsakovCincinnati$27K
- Sing Sing WayCincinnati$16K
- Mary StaatCincinnati$9K
- Elizabeth SchlaudeckerCincinnati$7K
- Grant PaulsenCincinnati$891
- Mark MurphyCincinnati$322
- David HaslamCincinnati$127
- Samir ShahCincinnati$101
- Sanjay JainCincinnati$51
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.